The Alzheimer's Drug Discovery Foundation (ADDF) supports promising research projects from around the world to develop new drugs for Alzheimer's and related dementias, including vascular, Lewy body, and frontotemporal dementias.
Our goal is to accelerate the development of therapies through four core areas:
- Drug discovery
- Clinical trials
The ADDF is interested in novel therapeutic approaches, including small molecules, biologics, and gene therapies. Because the mechanisms underlying Alzheimer's disease and related dementias are varied and complex, we maintain a diverse portfolio of drug targets. We invite you to explore our portfolio to learn more about funded projects, and visit our Funding Opportunities page for current Requests for Proposals (RFP) and upcoming deadlines.
Our Current Portfolio by Drug Targets
• Calcium regulation
Genetics & Epigenetics
• Cognitive and functional outcomes
Mitochondria & Metabolic Function
Synaptic Activity & Neurotransmitters
Please note: The ADDF no longer funds anti-amyloid approaches and has limited interest in funding cholinesterase inhibitor programs.
If you are considering applying for funding, log into or a create an account in the ADDF Grants Portal.